89bio, Inc. Launches Proposed Public Offering
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a biopharmaceutical company focused on innovative therapies for liver and cardiometabolic diseases, has announced a significant underwritten public offering. This initiative involves $250 million worth of its common stock or, alternatively for certain investors, pre-funded warrants granting the purchase rights to the company’s shares.
Enhancing Financial Resources
The company is also planning to give underwriters an option to purchase an additional $37.5 million of shares within a 30-day period at the anticipated public offering price. This step aims to boost their financial resources to support the growing clinical needs.
Utilizing the Proceeds
89bio intends to allocate the net proceeds from this offering toward essential clinical activities, focusing on the development of pegozafermin. The funding will cover manufacturing costs and other corporate purposes, including working capital and operational expenses.
Leading Financial Partners
Goldman Sachs & Co. LLC, Leerink Partners, and BofA Securities are facilitating this offering as lead book-running managers, while Cantor Fitzgerald is serving as a book-running manager. Their roles are crucial in ensuring the offering is effectively managed and executed.
Regulatory Compliance
To ensure compliance with legal standards, an automatically effective shelf registration statement regarding this offering has been filed with the Securities and Exchange Commission (SEC). The offering will only be conducted using a prospectus, which includes a prospectus supplement that forms part of an effective registration statement.
Investor Information
Investors interested in the offering can access further details through the SEC's website. The preliminary prospectus supplement and accompanying prospectus filed with the SEC provide comprehensive insights into the offering and the company.
Important Contacts for Investors
For direct inquiries, interested investors can contact the following:
- Goldman Sachs & Co. LLC:
- Attention: Prospectus Department, 200 West Street, New York, NY 10282
- Phone: (866) 471-2526
- Email: annie.chang@89bio.com
For detailed information from Leerink Partners, potential investors can reach their Syndicate Department as well.
About 89bio
89bio is dedicated to offering innovative treatment solutions for patients suffering from liver and cardiometabolic diseases. Their primary focus remains on advancing pegozafermin through Phase 3 clinical trials aimed at treating metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Scientific Breakthroughs
Pegozafermin is a sophisticated fibroblast growth factor 21 analog designed with glycoPEGylated technology that enhances its biological efficacy through a remarkably extended half-life. This innovative approach is expected to revolutionize treatment options for patients in need.
Conclusion
In summary, 89bio is embarking on a pivotal journey to expand its resources through this public offering, which will significantly aid in their commitment to developing vital therapies for patients awaiting better treatment avenues. The involvement of esteemed financial partners further solidifies the strategic importance of this move for the company's future growth.
Frequently Asked Questions
What is the purpose of the public offering by 89bio, Inc.?
The public offering aims to secure capital for ongoing clinical activities, particularly in the development of its lead candidate, pegozafermin.
Who are the financial partners involved in the offering?
Goldman Sachs & Co. LLC, Leerink Partners, and BofA Securities are the lead book-running managers for this offering.
What is pegozafermin?
Pegozafermin is a fibroblast growth factor 21 analog developed by 89bio, targeting liver and cardiometabolic diseases.
How will the offering be conducted?
The offering will be conducted under a prospectus included in an effective shelf registration statement filed with the SEC.
Where can I find more information about the offering?
Investors can access detailed information about the offering through the SEC's website and the company's filed documents.
